You are here: Home » PTI Stories » National » News
Business Standard

Lupin inks pact with CSIR & DST

Press Trust of India  |  New Delhi 

Drug firm today said it has signed a pact with and for conducting research on a antibody therapeutic.

The agreement with "and (DST) is for conducting research on a continuous purification process development of a therapeutic," said in a BSE filing.

Senior - R&D, said: "Biotech is one of Lupins key growth drivers and we are committed to advancing our biotech R&D capabilities through strategic partnerships."

The collaboration with a premier institution like CSIR is an exemplary industry-academia collaboration that can further the development and commercialisation of biologics and biosimilars for a better and more affordable to customers across the globe, he added.

Shares of Lupin today closed at Rs 771.30 per scrip on BSE, up 1.41 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Thu, March 08 2018. 17:25 IST